Study #2022-0729
Methylnatrexone in resectable head and neck squamous cell carcinoma (MINK). A window of opportunity; pilot study.
MD Anderson Study Status
Enrolling
Treatment Agent
Methylnaltrexone
Description
To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Squamous Cell Carcinoma
Study phase:
Phase IV
Physician name:
Juan Cata
Department:
Anesthesiology & PeriOper Med
For general questions about clinical trials:
1-844-513-2253
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.